Events

Prime presents at 73rd annual Roy A. Bowers Pharmaceutical Conference on Nov. 11

Dinesh Kandanchatha, chief information and technology officer at Prime Therapeutics, will join panelists in a Nov. 11 discussion about pressing issues facing health care

Events

Every year, the Roy A. Bowers Pharmaceutical Conference, hosted by Rutgers University’s Ernest Mario School of Pharmacy, gathers experts from the health care sector to discuss pressing issues in the industry. This year, on Tuesday, Nov. 11, Prime Therapeutics (Prime)’s Chief Information and Technology Officer Dinesh Kandanchatha will join leaders from across the country in a panel discussion about some of the hottest topics in health.   

As part of this year's theme, "Innovating in a Time of Uncertainty: Strategies for Resilience and Sustainability," attendees can gain insights from health care leaders and innovators on: 

  • Leveraging artificial intelligence and technology to improve outcomes. 
  • Navigating affordability in chronic conditions. 
  • Trends in biosimilars, rare disease innovation and more. 

Event  

73rd annual Roy A. Bowers Pharmaceutical Conference 

Panel  

“Healthcare Trends and Management Opportunities” 

Date/time  

Tuesday, Nov. 11, 2025, 1–2:30 p.m. ET 

Check out the full conference agenda and register today to reserve your spot. 

About Prime Therapeutics

Prime Therapeutics logo

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn

Latest News

Login Portals
Compliance / Legal
Company
© 2025 Prime Therapeutics LLC